Abstract
To the Editor: Antimalarial agents have been used for the treatment of inflammatory diseases for the last half century, with hydroxychloroquine (HCQ) being approved in the United States in 19551. In addition to its common use in systemic lupus erythematosus (SLE), including cutaneous forms, it has also proven useful in treating rheumatoid arthritis (RA)2,3,4 and Sjögren’s syndrome5. In SLE, antimalarial agents have been shown to decrease disease activity and subsequent flares in both nonpregnant6 and pregnant patients7. Other potential benefits include a decreased risk of infection8 and thrombosis9 … Address correspondence to Dr. M. Kishimoto; E-mail: mkishimo{at}luke.or.jp
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
